|
Andrew L. Finn Pharm.D.is our Executive Vice President of Clinical Development and Regulatory Affairs. He joined the company in August 2004 upon our acquisition of Arius of which he was a co-founder. Dr. Finn has more than 21 years experience in pharmaceutical product development. Prior to his involvement with Arius he was from 2000 to 2003 Executive Vice President of Product Development at POZEN Inc. with responsibilities for formulation development non-clinical development clinical research and regulatory affairs. He participated in the activities leading up to the initial public offering and submitted marketing applications in Europe and the U.S. for 2 migraine products. From 1996 to 1999 Dr. Finn was Co-Founder and Chief Executive Officer of enVision Sciences a regulatory and clinical service company. From 1991 to 1996 he was Vice President of U.S. Clinical Research for Solvay Pharmaceuticals where he oversaw NDA submissions in the areas of inflammatory bowel disease osteoporosis prevention and treatment of obsessive-compulsive disorder. Prior to this he spent 10 years in positions of increasing responsibility at Glaxo Inc. where he oversaw a number of NDA submissions including Zofran for chemotherapy induced nausea and vomiting. Dr. Finn received his BS in Pharmacy from the University of North Carolina and his Doctorate from the University of Michigan. | 